Introduction In a recent interview with Proactiveinvestors.com, PainReform Ltd. s CEO, Ilan Hadar, shed light on the latest developments surrounding PRF-110 and its potential to address the concerning opioid epidemic. As a clinical-stage specialty pharmaceutical company, PainReform focuses on reformulating established therapeutics to provide safer and more effective solutions for pain management. This article explores the key insights shared by Hadar and highlights the significance of PRF-110 in tackling the current opioid crisis. PainReform s Remarkable Progress PainReform Ltd. has made significant strides in its mission to combat the opioid epidemic through the development of PRF-110. This...
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
